Sarepta Q3 Revenue Slips 5% as ELEVIDYS Declines, but Guidance Low End Raised $50M
SRPT is trading near its 52-week low of $14.68 (13% above the low).
Summary
Sarepta reported Q3 2026 total revenues of $381.4 million, down 5% from $399.4 million a year earlier, as ELEVIDYS sales fell on the narrower ambulatory-only label. The quarter produced a GAAP net loss of $28.5 million, or $0.27 per share, versus a $50.6 million loss a year ago, while non-GAAP net income came in at $15.6 million, or $0.13 per share. Cost of sales included a $62.0 million take-or-pay charge tied to Catalent manufacturing obligations the company elected not to fulfill. Management raised the low end of full-year total net product revenue guidance by $50.0 million to $1.25-$1.3 billion and trimmed the high end of combined non-GAAP R&D and SG&A expense guidance by $25.0 million to $800-$825 million. The balance sheet holds $998.7 million in cash, cash equivalents, restricted cash and investments, which the company says funds the DM1 and FSHD programs through late-stage development. Multiple ascending dose data for SRP-1003 in DM1 and SRP-1001 in FSHD are expected in Q4 2026, with Phase 3 preparations already underway.
At the time of this announcement, SRPT was trading at $16.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $14.68 to $24.68. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.